Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

RA Shortens Life Expectancy of Patients with RA & Increases Healthcare Costs

Arthritis & Rheumatology  |  Issue: May 2021  |  April 27, 2021

Introduction & Objectives

The personal and societal burdens imposed by rheumatoid arthritis (RA) in terms of premature mortality and high medical expenditures is high. With advancements in treatment in recent decades, mortality has decreased, while medical expenditures have increased. Investigators have conventionally used the standardized mortality rate to estimate the disease impact on patients, but Chiu et al. believe the impact of RA would be more easily understood by lay people if we could inform them of the life years lost due to the disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This study was undertaken to estimate the cumulative incidence rate of RA in the Taiwanese population aged 16–84 years, and the life expectancy, loss of life expectancy and lifetime healthcare expenditures for incident RA in Taiwan after 2003, when biologics began to be prescribed.

Methods

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Chiu et al. obtained all claims data from 1999–2016 from the National Health Insurance program of Taiwan and validated the data against the Catastrophic Illnesses Registry to establish the study cohort. They estimated the survival function for RA and extrapolated to lifetime using a rolling-over algorithm. For every RA case, they simulated sex-, age- and calendar year-matched referents from vital statistics and estimated their life expectancy. The difference between the life expectancy of the referent and the life expectancy of the RA patient was the loss of life expectancy for the RA patient.

Average monthly healthcare expenditures were multiplied by the corresponding survival rates and summed up throughout the lifetime to calculate the lifetime healthcare expenditures.

Results

A total of 29,352 new RA cases were identified from 2003–2016. There was a decreasing trend in cumulative incidence rate in those aged 16–84 for both sexes. Mean life expectancy after diagnosis of RA was 26.3 years, and mean lifetime cost was $72,953. RA patients had a mean loss of life expectancy of 4.97 years.

Women with RA survived one to two years longer than men with RA of the same age, which resulted in higher lifetime healthcare expenditures for women. Because the life expectancy for women in Taiwan is six to seven years higher that for men, the loss of life expectancy for women with RA was higher than that for men with RA.

Annual healthcare expenditures were similar for both sexes.

Conclusion

These findings indicate that since biologics became available, RA patients have lived longer and have higher lifetime healthcare expenditures, which should be monitored and evaluated for cost effectiveness.

Refer to the full study for all source material.

Excerpted and adapted from: Chiu Y-M, Lu Y-P, Lan J-L, et al. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: A nationwide cohort followed up from 2003 to 2016. Arthritis Rheumatol. 2021 May;73(5).

 

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologyhealthcare costslife expectancyResearchRheumatoid Arthritis (RA)Women

Related Articles

    Global Life Expectancy Rises, but People Live Sicker for Longer

    August 28, 2015

    LONDON (Reuters)—People around the world are living longer, but many are also living sicker lives for longer, according to a study of all major diseases and injuries in 188 countries. General health has improved worldwide, thanks to significant progress against infectious diseases, such as HIV/AIDS and malaria, in the past decade and gains in fighting…

    Mortality Rates Improve for Patients with Rheumatoid Arthritis

    October 1, 2014

    Emerging research suggests patients with RA are living longer, bolsters support for early aggressive treatment of RA

    Hepatitis C Virus Infection Associated with Rheumatoid Arthritis

    January 23, 2015

    Research finds patients with chronic HCV infection more likely to develop RA, especially men

    Studies Say People with Rheumatic Disease Face Work Challenges

    September 11, 2020

    Aleksandar Malivuk; Hryshchyshen Serhii; Iakov Filimonov; Krisha Vishinpir; Russamee; sutlafk; Svitlana Hulko; yangtak / shutterstock.com EULAR 2020 e-CONGRESS—People with rheumatic diseases have more difficulty than others leading a work life, and researchers are attempting to quantify just how long they are able to remain healthy and working compared with the general population. This topic is…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences